CTMX - CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors | Benzinga
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors.
"We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth and leadership in the field of conditionally activated, localized biologics. Zhen's patient-focused leadership and commitment to making a meaningful difference for cancer patients strongly aligns to our vision of transforming lives with safer, more effective therapies."
Dr. Su is an accomplished physician executive with nearly three decades of experience leading oncology research and development and commercial organizations. Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors. During his tenure at Marengo, Dr. Su has led the teams progressing the company's lead asset into clinical trials, grown its leading-edge pipeline, and brokered a $1.6 billion partnership with Ipsen.
Prior to joining Marengo, Dr. Su was senior vice president and global head of the oncology business franchise for Merck KGaA. Before that, he was the chief medical officer at EMD Serono. Dr. Su also held increasing leadership roles at Sanofi and GlaxoSmithKline. Before joining the industry, he served on the faculty of Duke University Medical School, where he led early oncology clinical studies focused on mRNA-based and cell-based immunotherapy, and at University of Florida, where he was the director of the cell and gene therapy program. Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).
"I am excited for the opportunity to join CytomX's board as the company ...